Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems.
Our study takes a further look at the apomorphine test in the psychoses and affective disorders, with special reference to the use of different diagnostic systems. Patients meeting Research Diagnostic Criteria (RDC) for schizophrenia, schizoaffective disorder, or manic disorder were included. In addition to the RDC, diagnosis was also made using the DSM-III and ICD-9. All patients underwent an evaluation of peak GH response to apomorphine administration. The results show that RDC and ICD-9 are similar, in that for both systems, a high GH response correlates with a schizoaffective disorder and distinguishes those patients significantly from manic patients. The DMS-III brings in some new dimensions, in that schizophreniform disorder (6-month cut-off) is distinguished from schizophrenia. In addition, patients with affective symptoms and mood-incongruent psychoses are more closely related to schizophreniform disorder than to classical manic disorder.
J
J
Hirschowitz
F P
FP
Zemlan
R J
RJ
Hitzemann
R L
RL
Fleischmann
D L
DL
Garver
D000328:Adult; D001058:Apomorphine; D001714:Bipolar Disorder / Q000175:diagnosis; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000097:blood / Q000175:diagnosis*; D011618:Psychotic Disorders / Q000097:blood / Q000175:diagnosis*; D012559:Schizophrenia / Q000175:diagnosis
D013006:Growth Hormone; D001058:Apomorphine